Shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) crossed above its 50-day moving average during trading on Thursday after the company announced better than expected quarterly earnings. The stock has a 50-day moving average of $18.96 and traded as high as $22.41. vTv Therapeutics shares last traded at $22.41, with a volume of 5,654 shares trading hands.
The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.04).
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the company. StockNews.com began coverage on vTv Therapeutics in a research report on Wednesday, April 16th. They set a "sell" rating on the stock. HC Wainwright initiated coverage on vTv Therapeutics in a research report on Wednesday, April 9th. They issued a "buy" rating and a $36.00 target price on the stock.
Get Our Latest Report on vTv Therapeutics
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. acquired a new position in vTv Therapeutics in the 4th quarter valued at $25,000. Geode Capital Management LLC raised its holdings in vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after acquiring an additional 1,327 shares in the last quarter. Finally, Connective Capital Management LLC acquired a new position in vTv Therapeutics in the 1st quarter valued at $162,000. 17.51% of the stock is owned by institutional investors and hedge funds.
vTv Therapeutics Stock Performance
The stock has a market capitalization of $67.79 million, a price-to-earnings ratio of -4.69 and a beta of 0.77. The company has a fifty day simple moving average of $19.09 and a two-hundred day simple moving average of $16.95.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Featured Articles
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
